Loading...
Market
HRO761 Effectiveness in Phase 1 Trials by End of 2025
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial results reported by NIBR, Vividion, or regulatory filings
Story
Breakthrough WRN Inhibitor HRO761 Targets MSI Cancers, Poised for Clinical Trials
Apr 24, 2024, 07:56 PM
Recent research has led to the discovery of a novel inhibitor, HRO761, targeting Werner Helicase (WRN), which shows synthetic lethality in microsatellite instability (MSI) cancers. This breakthrough, published in Nature, was achieved through chemoproteomic techniques that identified a covalent allosteric inhibitor of WRN. The research, spearheaded by NIBR and involving Vividion, marks a significant advancement in cancer treatment, particularly by transforming an ATP-competitive compound into an ATP-cooperative analogue. The development is poised for clinical testing to evaluate its effectiveness in human models of disease.
View original story
Similar markets
80-90% success • 50%
Below 80% success • 50%
High efficacy • 33%
Moderate efficacy • 33%
Low efficacy • 34%
Yes • 50%
No • 50%
Positive results • 33%
Neutral results • 34%
Negative results • 33%
Does not progress past Phase 1 • 25%
Completes Phase 1 but not Phase 2 • 25%
Completes Phase 2 but not Phase 3 • 25%
Advances to Phase 3 or beyond • 25%
More effective than existing treatments • 25%
Equally effective as existing treatments • 25%
Less effective than existing treatments • 25%
Ineffective • 25%
Gene Therapy • 25%
Neural Modulation • 25%
Pharmacological • 25%
Biological Therapy • 25%